Published in Biotech Business Week, December 26th, 2005
Ligand said the company, following its continued review of business, product assets, and current strategic position, believes it is appropriate to initiate an external process to explore strategic alternatives to enhance shareholder value. As a result, UBS was hired to assist the board of directors and management in this process.
The company also announced the filing of its form 10-K for fiscal year 2004 containing audited results for fiscal 2004, restated audited results for fiscal years 2003 and 2002, and a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.